| InspireMD Celebrates Successful ICI 2010 Meeting; Long-Term Data Validates MGuard as Potentially Important Tool in Modern Acute MI Therapy |
| Sanofi-aventis and Oxford University Collaborate to Conduct Oncology Research in India |
| Teysuno? (S-1) Receives CHMP Positive Opinion for Approval as First-Line Therapy for Advanced Gastric Cancer |
| Foundation Venture Capital Group Invests in Start-Up Company Working to Improve Mobility for People with Chronic Spinal Cord Injuries |
An ITG Majestic Market Research Study Indicates a Bright Future for Gilenya, Despite Concerns About Its Safety |
|
Feature Interview
| InspireMD Celebrates Successful ICI 2010 Meeting; Long-Term Data Validates MGuard as Potentially Important Tool in Modern Acute MI Therapy |
|
| InspireMD Celebrates Successful ICI 2010 Meeting; Long-Term Data Validates MGuard as Potentially Important Tool in Modern Acute MI Therapy |
| Sanofi-aventis and Oxford University Collaborate to Conduct Oncology Research in India |
| Teysuno? (S-1) Receives CHMP Positive Opinion for Approval as First-Line Therapy for Advanced Gastric Cancer |
| Foundation Venture Capital Group Invests in Start-Up Company Working to Improve Mobility for People with Chronic Spinal Cord Injuries |
An ITG Majestic Market Research Study Indicates a Bright Future for Gilenya, Despite Concerns About Its Safety |
|
| InspireMD Celebrates Successful |
InspireMD Celebrates Successful |
| Sanofi-aventis and Oxford University |
Sanofi-aventis and Oxford University |
|
|
|
|
